3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
17
Gastrointestinal Stromal Tumors
10
Neoplasms
5
Neoplasm Metastasis
4
Multiple Myeloma
4
Kidney Neoplasms
4
Urologic Neoplasms
2
Thyroid Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Meningioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Kidney Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Temozolomide
15
Radiotherapy
10
Radiation
8
Magnetic Resonance Spectroscopy
7
pembrolizumab
5
Specimen Handling
5
Ipilimumab
3
atezolizumab
2
Photons
2
Nivolumab
2
Biopsy
2
veliparib
1
selinexor
1
sargramostim
1
plerixafor
1
peposertib
1
pazopanib
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
montanide ISA 51
1
liposomal doxorubicin
1
gosha-jinki-gan
1
fluorodopa F 18
1
ferric pyrophosphate
1
efineptakin alfa
1
cemiplimab
1
cabozantinib
1
balstilimab
1
abexinostat
1
X-Rays
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gliosarcoma
×
Sunitinib
×
1 year
×
Clear all
No trials found.